Connect with us

Industry

Latin American cannabis clinic Zerenia arrives in UK – promising patients more ‘affordable’ access

The clinic has recently joined Project Twenty21 with the promise of making medical cannabis more accessible.

Published

on

Zerenia clinic: doctor holding medical cannabis
The clinic will initially prescribe for chronic pain and mental health conditions.

Latin American medical cannabis clinic, Zerenia, has launched in the UK, with a bid to improve patient access as it joins Project Twenty21.

Zerenia Clinics, which launched in the UK in recent weeks, has joined a growing number of clinics on Project Twenty21 (T21), as it aims to make medical cannabis more affordable for patients. 

The clinic also offers competitive costs, with consultation fees at £80. 

The clinic’s three doctors will initially prescribe for chronic pain and mental health, with the majority of patients so far seeking treatment for indications such as anxiety, ADHD, PTSD and insomnia.

Zerenia, which already has 14 clinics across Latin America, has treated around 14,000 patients with medical cannabis, and according to Zerenia’s UK clinical operations director, Freeda Solliman, mental health is the predominant indication prescribed for. 

Many of these patients now get their prescriptions funded via private insurers, a model which the clinic now hopes to replicate in the UK. 

“In Latin America we’ve built a body of evidence there to support private insurers to fund medical cannabis treatment,” Solliman told Cannabis Health.

“We’ve seen about 14,000 patients who have been treated with medical cannabis and a large number of those actually get their prescriptions funded by private insurers. That’s the kind of model that you want to bring here.”

Zerenia has partnered with T21, which subsidises the cost of prescriptions, to help build the growing body of evidence for the safety and efficacy of medical cannabis. 

“Our goals are quite well aligned, we want to build the evidence and we want to make medical cannabis more affordable for patients,” continued Solliman.

“We want to work to encourage the NHS first and foremost, but also private insurers to fund at least part of the costs involved in being treated with medical cannabis.”

She added: “We did our research to understand some of the bottlenecks in the industry and how hard it is for some patients to go through the process, so we wanted to support patients through that and try to offer them more of a seamless experience.”

Zerenia is now taking on new patients who wish to join T21, or those who may want to try a different clinic. 

Initial consultations for new patients are priced at £80, for those transfering from a different clinic, £40. Find more information here

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@handwmedia.co.uk / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.